Effectiveness of Microdosed GLP-1 in Improving Health, Quality of Life, and Longevity Measures: For Use in Healthy Individuals Ages 18-65 Who Seek to Improve Their Health and Longevity Through Low-dose (Microdosed) GLP1 Receptor Agonists

Registration

Registration

NCT07092605

Study type

INTERVENTIONAL

Allocation

RANDOMIZED

Phase

EARLY_PHASE1

Masking

SINGLE

Status

ENROLLING_BY_INVITATION

Enrollment

150

Start

2024-11-01

Primary completion

2025-11-01

Lead sponsor

AgelessRx

Conditions

Longevity; Quality of Life; Mood; Inflammation; Immune Health; Pain Management; Weight Management; Alertness

Interventions

DRUG:GLP-1; DRUG:Placebo

Results posted

FALSE

Registered primary outcomes

• Change in self-reported pain levels in participants microdosing GLP1s [6 months]
• Concentration of complete blood cells, as a measure of immunological health, in participants microdosing GLP1s [6 months]
• Concentration of basic metabolites (cholesterol, glucose, creatinine, sodium, potassium), as a measure of immunological health, in participants microdosing GLP1s [6 months]
• Change in mood in participants microdosing GLP1s [6 months]
• Change in heart rate variability in participants microdosing GLP1s [6 months]
• Changes in sleep patterns in participants microdosing GLP1s [6 months]
• Change in frequency of physical activity in participants microdosing GLP1s [6 months]